USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.28 | $-0.10 | $-0.29 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $4.05M | $13.70K | $0.00 |
Aeglea Biotherapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 7 | $-0.31 | $-0.36 | $-0.28 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 8 | $-0.98 | $-1.05 | $-0.85 |
| Dec 2022 | 8 | $-0.96 | $-1.57 | $0.56 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.31 | $-0.33 | $-0.29 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $-0.98 | $-1.02 | $-1.03 |
| Dec 2022 | 0 / 0 | $-1.02 | $-0.94 | $-0.92 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 5 | $550.00K | $0.00 | $1.37M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $17.58M | $13.70M | $23.20M |
| Dec 2022 | 5 | $7.29M | $0.00 | $25.90M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.28 | - | - |
| Aug 5, 2021 | Jun 2021 | $-0.17 | $-0.10 | 41.86% |
| May 10, 2021 | Mar 2021 | $-0.14 | $-0.28 | -100.57% |
| Mar 18, 2021 | Dec 2020 | $-0.33 | $-0.34 | -2.63% |
| Nov 5, 2020 | Sep 2020 | $-0.40 | $-0.29 | 27.26% |
| Aug 10, 2020 | Jun 2020 | $-0.43 | $-0.40 | 7.06% |
| May 7, 2020 | Mar 2020 | $-0.66 | $-0.57 | 13.19% |
| Feb 24, 2020 | Dec 2019 | $-0.66 | $-0.65 | 2.15% |
| Nov 6, 2019 | Sep 2019 | $-0.53 | $-0.66 | -23.99% |
| Aug 6, 2019 | Jun 2019 | $-0.48 | $-0.55 | -13.82% |
| May 7, 2019 | Mar 2019 | $-0.55 | $-0.59 | -6.85% |
| Mar 7, 2019 | Dec 2018 | $-0.37 | $-0.62 | -69.35% |
| Nov 8, 2018 | Sep 2018 | $-0.43 | $-0.54 | -25.00% |
| Aug 9, 2018 | Jun 2018 | $-0.35 | $-0.46 | -33.33% |
| May 8, 2018 | Mar 2018 | $-0.46 | $-0.49 | -6.41% |
| Mar 13, 2018 | Dec 2017 | $-0.53 | $-0.39 | 26.25% |
| Nov 7, 2017 | Sep 2017 | $-0.55 | $-0.48 | 12.89% |
| Aug 9, 2017 | Jun 2017 | $-0.48 | $-0.47 | 2.08% |
| May 9, 2017 | Mar 2017 | $-0.47 | $-0.47 | -0.45% |
| Mar 23, 2017 | Dec 2016 | $-0.51 | $-0.33 | 35.31% |
| Nov 9, 2016 | Sep 2016 | $-0.54 | $-0.47 | 13.57% |
| Aug 9, 2016 | Jun 2016 | $-0.42 | $-0.46 | -9.52% |
| May 19, 2016 | Mar 2016 | $-0.49 | $-0.35 | 27.63% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 18, 2021 | Dec 2020 | $-1.50 | $-1.60 | - |
| Feb 24, 2020 | Dec 2019 | $-2.48 | $-2.45 | - |
| Mar 7, 2019 | Dec 2018 | $-1.84 | $-2.11 | - |
| Mar 13, 2018 | Dec 2017 | $-1.95 | $-1.81 | - |
| Mar 23, 2017 | Dec 2016 | - | $-1.61 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $4.05M | - | - |
| Aug 5, 2021 | Jun 2021 | $12.15M | $13.70K | 0.00% |
| May 10, 2021 | Mar 2021 | $13.00M | $0.00 | - |
| Mar 18, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 5, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 10, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 7, 2020 | Mar 2020 | $3.36M | $0.00 | - |
| Feb 24, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 6, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 6, 2019 | Jun 2019 | $300.00K | $0.00 | - |
| May 7, 2019 | Mar 2019 | $300.00K | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $1.98M | $3.89M | 1.96% |
| Nov 8, 2018 | Sep 2018 | $1.16M | $2.38M | 2.05% |
| Aug 9, 2018 | Jun 2018 | $1.63M | $2.38M | 1.46% |
| May 8, 2018 | Mar 2018 | $1.07M | $1.51M | 1.41% |
| Mar 13, 2018 | Dec 2017 | $1.16M | $1.48M | 1.28% |
| Nov 7, 2017 | Sep 2017 | - | $1.26M | - |
| Aug 9, 2017 | Jun 2017 | - | $1.48M | - |
| May 9, 2017 | Mar 2017 | - | $982.00K | - |
| Mar 23, 2017 | Dec 2016 | - | $1.25M | - |
| Nov 9, 2016 | Sep 2016 | - | $1.15M | - |
| Aug 9, 2016 | Jun 2016 | - | $1.37M | - |
| May 19, 2016 | Mar 2016 | - | $859.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 18, 2021 | Dec 2020 | $0.00 | $21.84K | - |
| Feb 24, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $4.49M | $3.89M | -13.41% |
| Mar 13, 2018 | Dec 2017 | $4.88M | $5.21M | 6.66% |
| Mar 23, 2017 | Dec 2016 | - | $4.63M | - |
AGLE's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 7 analysts, the average EPS estimation for Aeglea Biotherapeutics's next quarterly earnings is $-0.28, with a low EPS estimation of $-0.33, and a high estimation of $-0.17.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.28, the last 2 month trend is $-0.31, and the 3 month trend is $-0.28.
Based on 5 analysts, the average revenue estimation is $4.05M, with a low revenue estimation of $0.00, and a high estimation of $9.50M.
Aeglea Biotherapeutics's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.
AGLE's earnings per share (EPS) was $-0.10, beating the consensus analysts forecast of $-0.17 by 41.86%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -64.29%, and higher than the same period a year before (Jun 2020) by -75.00%.
Revenues were $13.70K.
The company reported a net income of $-6.83K.Free cash flow for the quarter was $-17.93M , compared to $-19.98M last quarter and $-20.74M a year before.
AGLE ended the quarter with $5.29M in total debt, a decrease of -0.60% compared to the previous quarter, and an increase of 7.50% compared to the same quarter a year before.
Aeglea Biotherapeutics's previous annual earnings date was Mar 18, 2021 for its fiscal year ended Dec 31, 2020.
AGLE's earnings per share (EPS) was $-1.60, missing the consensus analysts forecast of $-1.50 by 6.67% , and higher than the previous year's EPS (Dec 2019) by -34.69%.
Revenues were $21.84K.
The company reported a net income of $-80.89M.
Aeglea Biotherapeutics reported a free cash flow of $-80.06M for its fiscal year, compared to $-67.18M a year ago.
The company ended the fiscal year with $5.45M in total debt, an increase of 7.60% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.